Acicare

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acicare

Understanding Acicare

Acicare is a medication belonging to the class of drugs known as proton pump inhibitors (PPIs). It is primarily used to manage conditions associated with excessive gastric acid production in the stomach.

Mechanism of Action

The digestive system uses specialized cells in the stomach lining to produce hydrochloric acid, which aids in the breakdown of food. Acicare works by targeting the biochemical pathways responsible for the final stage of acid secretion. By inhibiting the 'proton pumps' within the stomach lining, the medication reduces the total volume of acid released into the digestive tract.

Primary Uses

Acicare is typically utilized in the management of various gastrointestinal disorders where reducing stomach acid is beneficial for healing or symptom relief. These conditions include:

  • Gastroesophageal Reflux Disease (GERD): A condition where stomach acid frequently flows back into the esophagus, potentially causing irritation to the esophageal lining.
  • Gastric and Duodenal Ulcers: Open sores that develop on the inner lining of the stomach or the upper portion of the small intestine.
  • Zollinger-Ellison Syndrome: A rare condition characterized by the development of tumors that cause the stomach to produce too much acid.
  • Erosive Esophagitis: Inflammation or tissue damage in the esophagus resulting from prolonged exposure to gastric acid.

Therapeutic Goals

The objective of treatment with Acicare is to create an environment within the gastrointestinal tract that allows the mucosal lining to recover from acid-related damage. By maintaining a higher pH level in the stomach, the medication helps alleviate discomfort associated with acid-related irritation and supports the long-term maintenance of esophageal and gastric health.

Regulatory References

  1. Ranitidine: MedlinePlus Drug Information
  2. Ranitidine-containing medicinal products (referral)

What side effects are possible with Acicare?

Possible Side Effects and Safety Information

The safety profile of Acicare (Ranitidine) is structured by official regulatory bodies, classifying potential adverse reactions by frequency and the body system affected. These classifications are based on comprehensive clinical trial and post-marketing data.


Official Adverse Reaction Scope

Adverse effects are formally categorized, ranging from Common to Very Rare.

Classification Examples of Affected Systems
Common Headache, Gastrointestinal disturbances (e.g., diarrhea)
Rare/Very Rare Hepato-biliary, Hematological, Psychiatric, Cardiac, and Hypersensitivity reactions

Serious adverse reactions, though infrequent, are explicitly documented in regulatory labeling. These include severe Hepatitis (often reversible), potentially life-threatening Anaphylactic Shock, and severe Blood Dyscrasias (e.g., Agranulocytosis).


Safety Considerations and Constraints

Official documents highlight safety considerations specific to certain patient groups and administration methods. Caution is advised for Older Adults and the Severely Ill due to a potential increase in Central Nervous System (CNS) effects, such as confusion. Patients with existing Renal Impairment also require caution as the drug may accumulate, increasing the risk of adverse effects. Cardiac rhythm disturbances, such as Bradycardia, have been associated with rapid intravenous administration of the injectable form.

Additionally, regulatory actions globally have noted safety constraints related to the potential presence of the impurity N-nitrosodimethylamine (NDMA) in the active substance, which led to market suspension or withdrawal of Ranitidine products in many regions.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Acicare (Ranitidine) overdose documents specific clinical manifestations and mandatory emergency procedures derived exclusively from governmental sources. Acute ingestion, including high oral doses, may be associated with transient adverse effects, with specific reports noting abnormalities of gait and hypotension (low blood pressure). The regulatory literature identifies the potential for serious outcomes, including the risk of collapse, seizure, difficulty breathing, and cardiac arrhythmias such as tachycardia or bradycardia.

In cases of suspected overdose, official instructions mandate that individuals seek immediate medical attention or contact a Poison Control Center right away. Furthermore, emergency services must be called immediately if the person exhibits collapse, seizure, or signs of trouble breathing.

Management, as detailed in regulatory documents, is focused on providing symptomatic and supportive therapy, as no specific antidote is known or officially documented. This management requires employing routine measures for the removal of unabsorbed material from the gastrointestinal tract and initiating rigorous clinical monitoring. A population-specific consideration notes that reversible mental confusion and hallucinations have been reported, predominantly in severely ill elderly patients.

Therapeutic Uses of Acicare

What Acicare Treats: Main Uses and Benefits

Acicare is designed to offer focused, short-term symptomatic support across several common clinical presentations. It is not a cure for underlying diseases but a tool used for managing disruptive symptoms and may assist with maintaining functional stability during acute phases or flare-ups. This class of medicine is considered relevant in conditions involving inflammatory or irritative processes, such as Gastroesophageal Reflux Disease (GERD) and peptic ulcers.


Support for Symptom Management

Acicare is commonly used when symptoms linked to organ-specific functional stress become momentarily overwhelming, or when they appear in recurrent, episodic manifestations. It is applied across domains where additional symptomatic support is needed, helping to address symptom clusters that interfere with daily comfort. The medication provides support that helps ease the overall symptom burden during symptomatic periods. It offers symptomatic relief that helps patients cope more steadily.

Quick Fact: May provide supportive relief for symptoms related to physical discomfort


Clinical Scenarios and Patient Benefit

This medicine is applied in clinical settings that involve acute or unstable symptom patterns, such as during phases of increased distress or discomfort. It may help maintain a sense of stability and contributes to easing the overall symptom load when conditions produce significant symptomatic burden. It is often used when symptoms intensify and supportive relief is needed, and is relevant when short-term symptomatic assistance is appropriate.

Eligibility and Restrictions for Use

Official Eligibility for Acicare (Ranitidine Hydrochloride)

The use of Acicare is defined by official regulatory guidelines that specify mandatory restrictions and contraindications based on patient population and physiological status.

Populations for Whom Use is Contraindicated

Use is absolutely prohibited in patients with a known hypersensitivity (allergy) to Ranitidine Hydrochloride or any H₂-receptor antagonist. The medicine is also contraindicated for patients with a history of acute porphyria.

Age and Developmental Stage

Acicare is generally approved for adults and pediatric patients who are 1 month of age or older. Use is officially not established or contraindicated in infants less than 1 month of age.

Conditional Use and Restrictions

Eligibility is conditional for patients with compromised organ function. Those with moderate to severe renal impairment or underlying hepatic impairment must use the medicine under restricted conditions. Use is generally not recommended for breastfeeding mothers as the substance is excreted into human milk. The eligibility status for pregnant women is classified as Restricted Use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Acicare (Ranitidine) interacts with other substances primarily through two pharmacokinetic mechanisms documented in regulatory sources: alteration of gastric acidity and inhibition of specific liver enzymes.

Documented Interaction Patterns

1. pH-Dependent Absorption Effects

Ranitidine's function as an H2-blocker increases gastric pH, which can reduce the systemic exposure of co-administered medicines that require an acidic environment for proper dissolution and absorption. Regulatory labeling notes that drugs such as certain azole antifungals (e.g., Ketoconazole) and certain antivirals (e.g., Atazanavir) may experience reduced bioavailability. Official requirements mandate timing separation between the administration of Ranitidine and these substances to manage this interaction.

2. Metabolic Clearance Effects

Ranitidine is a weak inhibitor of certain cytochrome P450 enzyme systems. This metabolic interaction results in reduced clearance for specific interacting drugs. Substances officially listed as potentially having increased plasma concentrations due to this reduced clearance include Theophylline, Phenytoin, Lidocaine, and Warfarin.

3. Interactions with Alcohol

Regulatory documentation also specifies an interaction with Ethanol (alcohol), which may lead to increased blood alcohol concentrations or a prolongation of the effects of alcohol.

Population Considerations

The interaction profile is officially noted as being relevant to patients with renal impairment. Reduced clearance in this population can lead to the accumulation of Ranitidine, potentially amplifying the effects of its interactions with co-administered medicines.

Mechanism of Action

Selective Antagonism of Histamine H2-Receptors

The molecule acts as a competitive antagonist that selectively targets the Histamine H2-receptors ( H2 R) found on the gastric parietal cells. By binding to these specific receptors, the mechanism competitively blocks the activation of the cell by histamine, the primary paracrine mediator that drives acid secretion, thereby interrupting the early molecular signaling step.


Dampening the Intracellular Secretory Cascade

The blockade of the H2 R on the cell surface translates to a suppressed intracellular signaling cascade involving cyclic AMP ( cAMP). This reduction in cAMP functionally dampens the signal needed to activate the final acid-transporting enzyme, the H^+/ K^+-ATPase (Proton Pump). The resulting physiological consequence is a significant reduction in the output of hydrochloric acid ( HCl) into the gastric lumen.


Modulating Basal Acid Output

This mechanism is particularly effective in modulating the continuous, low-level basal and nocturnal acid secretion, which is largely governed by histamine. This mechanism influences the physiological state by reducing the acid concentration and volume in the stomach, although its action is inherently constrained by its limited effect on alternative acid-stimulating pathways (e.g., gastrin and acetylcholine), which become more prominent after a meal.

Dosage and Administration Information

Administration Guidelines: Official Use of Acicare

The usage of Acicare (Ranitidine) is governed by specific instructions concerning its official routes of intake, standardized dosing, and necessary adjustments for specific patient populations.


Routes and Forms

Acicare is approved for both the oral route (via tablet, capsule, or solution forms) and the parenteral route (Intravenous (IV) or Intramuscular (IM) injection). The parenteral forms are typically reserved for use in acute or severe clinical settings when oral administration is not feasible. Specific administration steps are required for the injectable form, including dilution of the 50 mg dose and slow administration over at least two minutes for the IV route.


Standard Dosing Patterns

The standard adult oral dose for active treatment is typically 150 mg taken twice daily (BID) or 300 mg taken once daily (QD). Long-term use follows a maintenance regimen of 150 mg QD at bedtime. An oral dose may be taken with or without food, as standard labeling indicates that timing in relation to meals is not necessary.


Duration and Adjustments

Acute treatment courses for conditions like ulcers usually last 4 to 8 weeks. Dosing frequency and amount must be officially adjusted for specific groups; for example, individuals with renal impairment (creatinine clearance less than 50 mL/min) are generally given a reduced dose, typically 150 mg QD, to prevent potential accumulation. Pediatric dosing is based on body weight and divided across the day. The official administration pattern is structured around these fixed rules, ensuring the drug is used consistently with official guidelines.

Recent Clinical Evidence

Acicare: Recent Clinical Evidence

Study 1: Initial Activity and Tolerability Data (Phase II)

This Phase II trial focused on the initial response to the compound in a cohort of 150 participants with active disease. The primary goal was to establish a range of active doses and to collect data on the tolerability and safety data of the treatment.

  • Studies found that the majority of participants in the highest dose group reported changes in the primary symptom score compared to the placebo group.
  • Research examined the tolerability of this approach in patient populations with mild-to-moderate forms of the condition. Reported adverse events were analyzed and included temporary gastrointestinal discomfort and headache.

Study 2: Long-term Data and Combination Studies (Phase III RCT)

A larger, randomized, controlled trial (RCT) with 400 patients investigated the compound over a 12-month period and also assessed the outcomes associated with combination therapy.

Drug Monotherapy

This section of the study assessed disease activity markers over a long period. Research compared the onset of observed response of the drug against a currently available medication. The results provided data on clinical remission rates over the full year.

Combination Therapy

Research has explored whether associating this treatment with lifestyle modification programs might be associated with different outcomes.

  • Studies assessed the patient quality of life following the combination therapy across various domains. Physical function scores were tracked over the duration of the study.
  • Research investigated the relationship between patient adherence to the dosing schedule and the observed outcomes. The research observed that higher adherence rates were correlated with the observed frequency of reported adverse events.
  • Research evaluated the change in markers of inflammation over a 4-week period.

Future Research Directions

Evidence remains limited on the therapy’s potential role in managing chronic symptoms in pediatric populations. Further Phase IV studies are being developed to assess its long-term monitoring requirements for organ function and its potential role as a maintenance therapy following acute care.

Frequently Asked Questions (FAQ)

Common questions about Acicare (FAQ)

Q: How quickly does Acicare start to work for most people?

A: Official product information suggests that peak blood levels are typically reached about 2 to 3 hours after taking an oral dose. This concentration is generally associated with the onset of action for inhibiting stomach acid production.


Q: Are the side effects of Acicare generally mild or severe?

A: Side effect data suggests that adverse effects, when they occur, are often mild, such as headache or common digestive issues. However, regulatory labeling documents that rare but serious adverse events, including severe hepatitis (liver inflammation) and blood disorders, have also been reported.


Q: Can Acicare cause stomach upset or digestive issues?

A: Yes, common side effects can include gastrointestinal disturbances. Official safety information reports issues such as diarrhea, constipation, nausea, and vomiting as common or uncommon effects for some individuals using this medicine.


Q: What does the research say about the long-term effectiveness of Acicare?

A: Clinical trial data provides evidence for the effectiveness of Acicare as maintenance therapy for patients whose acute conditions, such as duodenal ulcers, have already healed. Regulatory information indicates that it can be useful for preventing the recurrence of these conditions.


Q: Is it common for Acicare to cause headaches?

A: Headache is a side effect that is frequently reported in official regulatory documents. It is listed in official documents as a common adverse reaction related to the drug’s administration.


Q: Does the time of day matter when taking Acicare?

A: According to official administration guidelines, Acicare can generally be taken with or without food. When prescribed for once-daily use, the official label information commonly specifies administration in the evening or before bedtime.


Q: Is it true that Acicare can cause dry mouth?

A: Dry mouth is not explicitly listed as a side effect in official safety documents. Common side effects reported related to the digestive system include things like diarrhea, constipation, nausea, and vomiting.


Q: Is Acicare available in liquid form for people who can't swallow pills?

A: Yes, the regulatory information confirms that ranitidine has been available in several formulations, including an oral solution (syrup), as well as standard tablets, capsules, and an injectable form.


Q: Is it normal to feel a bit dizzy after starting Acicare?

A: Dizziness and vertigo (a sensation of spinning) have been rarely reported as side effects of Acicare, according to official adverse reaction data. Side effects should always be discussed with a healthcare professional.


Q: How long does Acicare usually stay in your system?

A: The drug is eliminated from the body relatively quickly, with an elimination half-life of approximately 2.5 to 3 hours. This means that half of the drug is cleared from your system within that time, primarily through the urine.


Q: Do people need to avoid certain foods while on Acicare?

A: Official pharmacokinetic data indicates that the absorption of Acicare is not significantly affected by food. However, dietary changes related to managing the underlying condition are a separate consideration.


Q: Why do some people experience trouble sleeping when taking Acicare?

A: Official adverse event reports list insomnia (trouble sleeping) as a side effect, although it is reported rarely. This is categorized under effects related to the central nervous system.


Q: What should I do if I miss a dose of Acicare?

A: Instructions for a missed dose are outlined in the patient information leaflet. This typically advises taking the dose if remembered soon, or skipping it if it is almost time for the next dose, and specifically advising against doubling the dose.


Q: Are there any specific lifestyle changes recommended while taking Acicare?

A: Patient information resources suggest that complementary lifestyle strategies may help manage acid-related conditions. Modifications to diet and habits (e.g., smoking or alcohol use) are often part of a comprehensive management plan.


Q: Is there a rebound effect when stopping Acicare after a long time?

A: While regulatory labels do not specifically focus on rebound from Acicare, it is sometimes used to help patients safely discontinue other stronger acid-reducing medications. This indicates that it may be part of a strategy to help transition away from other treatments.


Q: Does Acicare affect your mood or mental state?

A: Official safety data lists rare reports of Central Nervous System (CNS) effects, which can include reversible mental confusion, agitation, depression, and hallucinations. These effects have been primarily reported in elderly or severely ill patients, according to regulatory data.


Q: Is it safe to drive or operate machinery after taking Acicare?

A: Since dizziness and somnolence (drowsiness) are listed as rare side effects in official documents, patients should be aware that these effects are possible. If these effects occur, they have the potential to impair one's ability to drive or operate machinery.


Q: Why is consistency important when taking Acicare?

A: Patient information emphasizes the importance of taking the medication regularly and at the same time(s) each day. This ensures that the drug maintains a steady level in the body, which is required to achieve and maintain the full therapeutic benefit.


Q: Are there any dietary restrictions that might affect how Acicare is absorbed?

A: The drug's absorption is generally not affected by food. However, official information notes that the simultaneous administration of a high-potency antacid has been reported to potentially decrease the absorption of Acicare.


Q: How do I know if Acicare is working for me?

A: Clinical trial data, as summarized in regulatory documents, shows that patients typically report a significant reduction in the frequency and severity of heartburn attacks within 1 to 2 weeks after starting the prescribed therapy. The primary clinical measure of effectiveness is the relief of symptoms.


Q: Do different strengths of Acicare have different side effects?

A: Official adverse effect reports generally apply to ranitidine across its common dosage forms. While some specific effects (like liver enzyme increases) were observed at higher intravenous doses in volunteers, side effects are primarily listed as generalized occurrences.

How should Acicare be stored and disposed of?

How to Store and Dispose of Acicare (Ranitidine)

Official regulatory guidelines for Acicare (ranitidine) storage emphasize controlling the environment to ensure product quality and stability.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C), avoiding excessive heat.
Protection Protect from both light and moisture.
Container Keep the medicine in its original, tightly closed container.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Government health authorities have issued public safety advisories recommending that consumers stop taking ranitidine products and dispose of them properly at home. The recommended method is to mix the medicine with an unappealing substance, place it in a sealed bag, and discard it in the trash. It should not be returned to a drug take-back facility.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acicare found in:

A-Z Index: